UTHR UNITED THERAPEUTICS Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: UTHR

Price (delayed)

$513.12

Market cap

$22.01B

P/E Ratio

16.97

Dividend/share

N/A

EPS

$30.24

Enterprise value

$20.2B

?
Relative Growth: Rel. Growth: 79
Relative Strength: Rel. Strength: 56
Relative Valuation: Rel. Valuation: 58
Relative Profitability: Rel. Profitability: 94

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to ...

Highlights
The company's EPS rose by 9% YoY and by 3.3% QoQ
UNITED THERAPEUTICS's net income has increased by 6% YoY
The quick ratio has declined by 25% year-on-year but it has increased by 19% since the previous quarter
The equity has declined by 11% year-on-year but it has increased by 8% since the previous quarter
The stock's P/E is 18% above its 5-year quarterly average of 14.4
The gross margin has declined by 3.3% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.unither.com
Peers: LLY GILD TEVA PFE

Key stats

What are the main financial stats of UTHR

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-1.51%
1 week
2.68%
1 month
-4.24%
1 year
65.17%
YTD
5.31%
QTD
-5.3%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$3.15B
Gross profit
$2.72B
Operating income
$1.4B
Net income
$1.31B
Gross margin
86.1%
Net margin
41.6%
UNITED THERAPEUTICS's net income has increased by 6% YoY
The company's operating margin fell by 6% YoY
The operating income has contracted by 3.2% YoY and by 2.3% from the previous quarter
The net margin has grown by 3% YoY and by 2.5% from the previous quarter

Price vs fundamentals

How does UTHR's price correlate with its fundamentals

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
UTHR P/E details
P/E
16.97
P/B
3.4
P/S
6.93
EV/EBIT
12.75
EV/EBITDA
12.05
EV/Sales
6.41
The stock's P/E is 18% above its 5-year quarterly average of 14.4
The company's EPS rose by 9% YoY and by 3.3% QoQ
UTHR's price to book (P/B) is 42% higher than its 5-year quarterly average of 2.4 but 2.9% lower than its last 4 quarters average of 3.5
The equity has declined by 11% year-on-year but it has increased by 8% since the previous quarter
The stock's P/S is 26% above its 5-year quarterly average of 5.5
The company's revenue rose by 2.5% YoY

Efficiency

How efficient is UNITED THERAPEUTICS business performance
UNITED THERAPEUTICS's return on assets has increased by 9% YoY and by 4.7% QoQ
The ROE has grown by 8% YoY and by 5% from the previous quarter
The company's return on sales fell by 6% YoY and by 2.1% QoQ
The ROIC has grown by 2.3% from the previous quarter

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The quick ratio has declined by 25% year-on-year but it has increased by 19% since the previous quarter
The current ratio has contracted by 21% YoY but it has grown by 20% from the previous quarter
The debt is 100% less than the equity
The equity has declined by 11% year-on-year but it has increased by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.